type 2 drug market will nearly double

[Cowboyjim]

Decision Resources finds that the type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion in 2011 to nearly $50 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The main factors fueling this growth are an increasing drug-treated patient population and a large pipeline of products expected to launch during this period.

The dipeptidyl peptidase IV (DPP-IV) inhibitor drug class will continue to experience robust growth, given their increasing use in the second-line setting, and will hold a 28 percent market share by 2021. Merck’s first-in-class DPP-IV inhibitor, sitagliptin (Januvia/Xelevia), will remain the leading agent in the class while other agents struggle to differentiate themselves, owing to their lack of significant clinical advantages over Januvia. The glucagon-like peptide-1 (GLP-1) receptor agonist class will also experience strong growth with major-market sales forecasted to reach nearly $8 billion by 2021. Although these agents are expensive and require injections, they have a strong efficacy profile and can elicit weight loss.

Additionally, SGLT-2 inhibitors—most notably AstraZeneca/Bristol-Myers Squibb’s dapagliflozin and Johnson & Johnson’s canagliflozin—are also expected to have an impact on the treatment paradigm for type 2 diabetes.
“Interviewed thought leaders consider the SGLT-2 inhibitors the most interesting agents that will emerge during the forecast period based on their weight-loss efficacy, versatility and low risk of hypoglycemia,” said Decision Resources Therapeutic Area Director Donny Wong, Ph.D. “We anticipate that dapagliflozin, the lead compound in this class, will launch in Europe in late 2012.”

The findings also reveal that usage of the PPAR-gamma agonist class will continue to decline through 2021, given the safety issues surrounding both GlaxoSmithKline’s Avandia (rosiglitazone) and Takeda’s Actos (pioglitazone), as well as the generic erosion of pioglitazone.
http://finance.yahoo.com/news/type-2-diabetes-drug-market-140000517.html

 

[xyzzy]

Decision Resources finds that the type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion in 2011 to nearly $50 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The main factors fueling this growth are an increasing drug-treated patient population and a large pipeline of products expected to launch during this period.

The dipeptidyl peptidase IV (DPP-IV) inhibitor drug class will continue to experience robust growth, given their increasing use in the second-line setting, and will hold a 28 percent market share by 2021. Merck’s first-in-class DPP-IV inhibitor, sitagliptin (Januvia/Xelevia), will remain the leading agent in the class while other agents struggle to differentiate themselves, owing to their lack of significant clinical advantages over Januvia. The glucagon-like peptide-1 (GLP-1) receptor agonist class will also experience strong growth with major-market sales forecasted to reach nearly $8 billion by 2021. Although these agents are expensive and require injections, they have a strong efficacy profile and can elicit weight loss.

Additionally, SGLT-2 inhibitors—most notably AstraZeneca/Bristol-Myers Squibb’s dapagliflozin and Johnson & Johnson’s canagliflozin—are also expected to have an impact on the treatment paradigm for type 2 diabetes.
“Interviewed thought leaders consider the SGLT-2 inhibitors the most interesting agents that will emerge during the forecast period based on their weight-loss efficacy, versatility and low risk of hypoglycemia,” said Decision Resources Therapeutic Area Director Donny Wong, Ph.D. “We anticipate that dapagliflozin, the lead compound in this class, will launch in Europe in late 2012.”

The findings also reveal that usage of the PPAR-gamma agonist class will continue to decline through 2021, given the safety issues surrounding both GlaxoSmithKline’s Avandia (rosiglitazone) and Takeda’s Actos (pioglitazone), as well as the generic erosion of pioglitazone.
http://finance.yahoo.com/news/type-2-diabetes-drug-market-140000517.html

In my opinion none of the diabetic drugs apart from insulin are particularly effective unless you do lifestyle changes with them and then the correct lifestyle choices will outweigh the meds effectiveness anyway.

Take a look here for example http://en.wikipedia.org/wiki/Anti-diabetic_medication Most drugs offer around a 0.5 to 1% reduction in hBA1c the exceptions being Metformin which gets a 1 to 2% and some of the sulfureas like Glic similar results. Even the new much touted SGLT-2 meds like Dapagliflozin where you end up peeing out the glucose are not particularly effective in my mind. Read here says the clinic trails reduced hBA1c by 0.9% on top of using Metformin http://en.wikipedia.org/wiki/Dapagliflozin If you look back at the initial research on SGLT-2 meds then even then the claim was they could only be twice as good as Metformin see here for example http://www.medscape.org/viewarticle/578176 If you look at the chart this "superdrug" at its 50mg dose gives you around a 1.7 mmol drop in blood levels (once you convert from mg/dl). I reckoned I got 0.5mmol from just plain Cinnamon! So all that research cash has in my mind produced a drug 3 times more powerful than quaffing a couple of Cinnamon capsules.

How much more use would all that time, money and effort been if it had been used to educate and advocate a method that gave me a 6% drop in hBA1c in 3 months namely just changing my diet to restrict the starchy carbs I use to eat. I'm also of the opinion that if you don't want to change your diet or make the major life style changes the safest bet is probably just to go on insulin and be done with it.

 

[Cowboyjim]

How much more use would all that time, money and effort been if it had been used to educate and advocate a method that gave me a 6% drop in hBA1c in 3 months namely just changing my diet to restrict the starchy carbs I use to eat. I'm also of the opinion that if you don't want to change your diet or make the major life style changes the safest bet is probably just to go on insulin and be done with it.

Ooh err... It has crossed my mind many times too. I suppose that in extremis we might conclude that some kind of conspiracy is afoot. If I had the nerve I might experiment and just eat what I like and do little exercise up to the point where I have my next HbA1c.... two met a day with meals and keep my fingers and toes crossed (while I still have them). Maybe this is irresponsible tho.

As I have waffled on about in other threads, my GP thinks the boy done well... more that he takes his pills often and they so agree with him, in fact they work fine so no need to change em, well done! What a load of..... he wasn't much interested in what else I might have been doing re diet etc.

Another experiment would be to dump the met and eat even more tightly and use the meter more often... my bet is on this one being the safer option. 8)

 

[xyzzy]

Ooh err... It has crossed my mind many times too. I suppose that in extremis we might conclude that some kind of conspiracy is afoot. If I had the nerve I might experiment and just eat what I like and do little exercise up to the point where I have my next HbA1c.... two met a day with meals and keep my fingers and toes crossed (while I still have them). Maybe this is irresponsible tho.

Coming from a science background when I first joined the forum I use to object to the "big pharma conspiracy" theory but nowadays I'm not so sure. Nowadays I'm more inclined to simply believe it's mainly political in that to admit that low carb works means governments and their health care systems would have to admit their dietary policies have been wrong for the last 40 years or so. If it takes 23 years to get the state to admit it lied about the Hillsborough disaster then that is nothing compared to getting it to admit its entire national dietary policy has been wrong. In that climate it's little wonder Big Pharma comes in a makes a buck that's just capitalism at work and to be frank my attitude to capitalism is its fine so long as there are equivalent state controlled laws / morals to balance things out. It's also why I am such a supporter of the Swedes as their government has admitted it got it wrong as is making changes.

As I have waffled on about in other threads, my GP thinks the boy done well... more that he takes his pills often and they so agree with him, in fact they work fine so no need to change em, well done! What a load of..... he wasn't much interested in what else I might have been doing re diet etc.

Another experiment would be to dump the met and eat even more tightly and use the meter more often... my bet is on this one being the safer option. 8)

The level of education of our GP's seems lacking. As you say many take credit for when their patients actually sort things out for themselves by doing their own research and are quick to write off people as "they just don't want to listen / change" to those who they tell their failing 40 year old dogma to.

I actually don't mind Metformin. It looks to do what it says it does and seems to be pretty benign. Probably a biased view as I never get any side effects others mention even on the bog standard stuff.

Keep posting btw I always find your posts interesting